---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-006289"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:56:54.812303+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GeoVax reports 2023 net loss of $26.0M, cash drops to $6.5M; pipeline advances

## Summary
- Net loss widened to $26.0M in 2023 from $14.0M in 2022, driven by higher R&D costs ($20.7M vs $9.1M).
- Cash balance fell to $6.5M at Dec 31, 2023, from $27.6M a year earlier, reflecting clinical spending.
- Phase 2 trials of Covid vaccine GEO-CM04S1 continue; interim CLL booster data expected H1 2024.
- Gedeptin Phase 1/2 for head & neck cancer completed; expanded Phase 2 plans anticipated in 2024.
- Appointed Dr. J. Marc Pipas as Executive Medical Director, Oncology, to lead clinical development.

## SEC filing metadata
- accession: 0001437749-24-006289
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/0001437749-24-006289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/govx20240228_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-006289
- JSON: https://secwatch.observer/filing/0001437749-24-006289.json
- Plain text: https://secwatch.observer/filing/0001437749-24-006289.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/0001437749-24-006289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.